Pfizer's drug chief opened up his playbook yesterday at a San Francisco investment conference. Ian Read, president of worldwide pharmaceutical operations, confided worries about its top seller,
> Bayer got the FDA's blessing to market its Campath leukemia drug as a first-line treatment against the disease; previously, Campath was only approved for use when other therapies had failed.
At this weekâ€™s Bear Stearns Healthcare Conference, Pfizer discussed its plans for the future with analysts. As we all know, Pfizer is facing a major loss of sales when its best-selling drug
When does good news feel almost bad? When a blockbuster drug is deemed the juiciest on the market--but the wolves are circling. If this sounds like Lipitor to you, you're right. Today, the Pfizer
> Cell Therapeutics has decided to bypass an interim analysis ofÂ its non-Hodglin's lymphoma drug candidate Pixantrone. Instead, researchers say they will conduct a full analysis after the trial
Speaking of Pfizer, the company announced results from a new trial that showed statin-switching isn't such a good idea. Lipitor patients who switched to simvastatin saw their risk of cardio events
Who's first out of the gate on a generic Razadyne? Indian drug maker Ranbaxy announced today that it got the FDA's tentative nod for its version of the dementia treatment--but so did Sun
It's not easy being a global pharmaceuticals company. First, you have to develop drugs--and then you have to sell them, not only to your home country, but around the world. And there lies the rub,
> Pfizer's request for a reissued Lipitor patent was stamped "Rejected" by the U.S. Patent and Trademark Office--but the decision is only preliminary, so the drug maker can still hope for extended
> There's big trouble at Pfizer, where profit plunged 48 percent in the second quarter as new generics ate up market share and Lipitor sales floundered.